Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20942439 | 0.92 | CHRNB2 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL12775072 | 0.87 | CHRNB2 (0.30) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL12557812 | 0.86 | KDM4E (0.31) | — | |
| SCHEMBL21883665 | 0.85 | — | — | |
| SCHEMBL19013814 | 0.85 | — | — | |
| SCHEMBL4757755 | 0.85 | — | — | |
| SCHEMBL6965211 | 0.78 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL733735 | 0.78 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL12638492 | 0.77 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL16316868 | 0.77 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501483-B2 | Enamines and diastereo-selective reduction of enamines | ALLERGAN, INC. (US) | 2019-12-10 | — | — | US | disclosed |
| US-20190119304-A1 | ENAMINES AND DIASTEREO-SELECTIVE REDUCTION OF ENAMINES | ALLERGAN, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20080009489-A1 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIAN PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009489-A1 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | NR5A1, AR, CYP17A1 | CHRNB2 2541/4885CHRNB4 3022/4885CHRNA3 2641/4885 |
| US-10501483-B2 | Enamines and diastereo-selective reduction of enamines | ENY2, PNMT, CHRM1 | CHRNB2 528/4885CHRNB4 324/4885CHRNA3 401/4885 |
| US-20190119304-A1 | ENAMINES AND DIASTEREO-SELECTIVE REDUCTION OF ENAMINES | ENY2, PNMT, CHRM1 | CHRNB2 528/4885CHRNB4 324/4885CHRNA3 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.